[Profound survival benefit with concurrent chemotherapy: insights from a Chinese phase III trial in older patients with esophageal cancer]
Strahlenther Onkol
.
2022 May;198(5):500-502.
doi: 10.1007/s00066-022-01921-6.
Epub 2022 Mar 14.
[Article in German]
Authors
Claudia Schweizer
1
,
Rainer Fietkau
1
,
Florian Putz
2
Affiliations
1
Strahlenklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstr. 27, 91054, Erlangen, Deutschland.
2
Strahlenklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstr. 27, 91054, Erlangen, Deutschland. florian.putz@uk-erlangen.de.
PMID:
35286400
PMCID:
PMC9038893
DOI:
10.1007/s00066-022-01921-6
No abstract available
Publication types
Clinical Trial, Phase III
Comment
MeSH terms
Aged
Chemoradiotherapy
China
Esophageal Neoplasms* / drug therapy
Humans